Legal Representation
Attorney
Rob LeBlanc
USPTO Deadlines
Next Deadline
1535 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-10-03)
Due Date
October 03, 2029
Grace Period Ends
April 03, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
31 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 22, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Apr 22, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 22, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Apr 22, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 22, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Oct 3, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 3, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jul 18, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 18, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 28, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 12, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 1, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 31, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 31, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 3, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 3, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 3, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 2, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 15, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Feb 15, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 15, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Feb 14, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Feb 14, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 14, 2023 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
| Feb 14, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 14, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 14, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jun 2, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Jun 2, 2022 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
| May 18, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 17, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemicals for use in science; chemical compositions and agents for use in science; chemical preparations for use in the manufacture of pharmaceutical drugs; biological preparations for use in science; chemicals for biotechnological manufacturing processes; diagnostic preparations used for scientific or research use; reagents used for scientific or research use; proteins in raw material form for scientific or research use; none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers
Class 005
Pharmaceuticals, medicinal and veterinary preparations for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; diagnostic preparations for medical and veterinary use; medicines and biotechnological preparations for medical use for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; biological and chemical reagents for medical use; pharmaceutical drugs for medical purposes for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; none of the aforesaid goods being for the treatment and care of wounds and none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers
Class 042
Scientific and technological services, namely, scientific analysis, testing, engineering, development, research, and design in the field of drug discovery and the identification and development of pharmaceutical and medicinal preparations; consultancy relating to product research and development in the field of pharmaceutical and medicinal preparations for therapeutic use; research and development in the field of medical diagnostics; biotechnological and chemical testing; research and development in the pharmaceutical, chemical and biotechnological fields; research and development in the field of medicinal preparations; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers
Classification
International Classes
001
005
042